{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:38:51Z","timestamp":1777473531540,"version":"3.51.4"},"reference-count":33,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with large B-cell lymphoma (LBCL) are at increased risk of heart failure (HF) potentially due to anthracycline-based chemotherapy. However, associations with LBCL treatment intensity, HF subtype, and outcome remain undercharacterized. We conducted a nationwide cohort study of 8453 Swedish patients diagnosed with LBCL (median age 70 years) between 2007 and 2022 and 71\u2009506 matched population comparators without a history of HF. The 5-year cumulative incidence of new-onset HF among patients was 8.1% overall, corresponding to a twofold increased rate, driven mainly by nonischemic HF (hazard ratio [HR]nonischemic, 2.33; 95% confidence interval [CI], 2.16-2.50) and less by ischemic HF (HRischemic, 1.30; 95% CI, 1.04-1.62). An increased rate of new-onset nonischemic HF remained after 2 years of follow-up (HR, 1.78; 95% CI, 1.60-1.94). Few patients had reduced intensity treatment (4 R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone], n = 84) of whom none developed HF. Patients selected for intensive treatment (eg, R-CHOEP with etoposide or dose-adjustment [R-DA-EPOCH]) were not at higher risk of HF compared with those treated with standard R-CHOP (HR, 0.73; 95% CI, 0.58-0.92), although unmeasured differences in baseline fitness or frailty may have influenced treatment selection. After HF onset, patients with LBCL had consistently higher all-cause (but not cardiovascular) mortality than comparators. Our findings indicate that patients with LBCL face a sustained long-term risk of nonischemic HF, highlighting the importance of survivorship care and vigilant HF symptom screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018515","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:38:27Z","timestamp":1770233907000},"page":"2754-2764","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-9285","authenticated-orcid":false,"given":"Sissel Johanne","family":"Godtfredsen","sequence":"first","affiliation":[{"name":"1Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0693-3851","authenticated-orcid":false,"given":"Fanny","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[{"name":"2Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-4728","authenticated-orcid":false,"given":"Sara","family":"Harrysson","sequence":"additional","affiliation":[{"name":"2Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"3Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-8670","authenticated-orcid":false,"given":"Kristian","family":"Kragholm","sequence":"additional","affiliation":[{"name":"1Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarec C.","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"2Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"4Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"5Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"6Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"2Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"3Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-0573","authenticated-orcid":false,"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"2Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"6","key":"2026042809464640900_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2026042809464640900_bib2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/bjh.20104","article-title":"Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies","volume":"206","author":"Harrysson","year":"2025","journal-title":"Br J Haematol"},{"issue":"4","key":"2026042809464640900_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026042809464640900_bib4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"2026042809464640900_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"issue":"3","key":"2026042809464640900_bib8","first-page":"CD005008","article-title":"Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy","volume":"3","author":"van Dalen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2026042809464640900_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ejh.14275","article-title":"Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: a Danish observational population-based study","volume":"113","author":"Rask Kragh Jorgensen","year":"2024","journal-title":"Eur J Haematol"},{"issue":"10216","key":"2026042809464640900_bib10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"2026042809464640900_bib11","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026042809464640900_bib12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global variations in heart failure etiology, management, and outcomes","volume":"329","author":"Investigators","year":"2023","journal-title":"JAMA"},{"key":"2026042809464640900_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/1651-226X.2024.40431","article-title":"The National Swedish Lymphoma Register - a systematic validation of data quality","volume":"63","author":"Ekstrom Smedby","year":"2024","journal-title":"Acta Oncol"},{"issue":"9","key":"2026042809464640900_bib14","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1080\/10428194.2022.2064982","article-title":"Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study","volume":"63","author":"Juul","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026042809464640900_bib15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure","volume":"69","author":"Mantel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2026042809464640900_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer","volume":"62","author":"Hasin","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2026042809464640900_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1747493018778713","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke","volume":"13","author":"Sacks","year":"2018","journal-title":"Int J Stroke"},{"issue":"5","key":"2026042809464640900_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.15603","article-title":"Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines","volume":"183","author":"Baech","year":"2018","journal-title":"Br J Haematol"},{"issue":"9623","key":"2026042809464640900_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","article-title":"Global burden of blood-pressure-related disease, 2001","volume":"371","author":"Lawes","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"2026042809464640900_bib20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"2026042809464640900_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12885-017-3696-4","article-title":"Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy","volume":"17","author":"Ballotari","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"2026042809464640900_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.2.2.120","article-title":"Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study","volume":"2","author":"Kannel","year":"1979","journal-title":"Diabetes Care"},{"issue":"21","key":"2026042809464640900_bib23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJM198711193172102","article-title":"Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes","volume":"317","author":"Willett","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"2026042809464640900_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/euhj.1998.1194","article-title":"Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh artery study","volume":"20","author":"Price","year":"1999","journal-title":"Eur Heart J"},{"issue":"2","key":"2026042809464640900_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0025-7125(16)30355-8","article-title":"The health consequences of smoking","volume":"76","author":"Newcomb","year":"1992","journal-title":"Med Clin North Am"},{"issue":"34","key":"2026042809464640900_bib26","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026042809464640900_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/eurjhf\/hft064","article-title":"The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden","volume":"15","author":"Zarrinkoub","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"2026042809464640900_bib28","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"2026042809464640900_bib29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ejhf.838","article-title":"The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets","volume":"19","author":"Zaman","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2026042809464640900_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2026042809464640900_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/abm\/kaac054","article-title":"Changes in population health-related behaviors during a COVID-19 surge: a natural experiment","volume":"57","author":"Delgado-Ortiz","year":"2023","journal-title":"Ann Behav Med"},{"key":"2026042809464640900_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2340\/1651-226X.2024.35238","article-title":"Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study","volume":"63","author":"Ekberg","year":"2024","journal-title":"Acta Oncol"},{"key":"2026042809464640900_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"5","key":"2026042809464640900_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ejheart.2004.12.007","article-title":"The validity of a diagnosis of heart failure in a hospital discharge register","volume":"7","author":"Ingelsson","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2026042809464640900_bib35","first-page":"36","article-title":"Validity of heart failure diagnoses made in 2000-2012 in western Sweden","volume":"7","author":"Schaufelberger","year":"2020","journal-title":"ESC Heart Fail"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2754\/2514231\/blooda_adv-2025-018515-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2754\/2514231\/blooda_adv-2025-018515-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:47:05Z","timestamp":1777384025000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/8\/2754\/566422\/Incidence-timing-and-prognosis-of-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018515","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,28]]},"published":{"date-parts":[[2026,4,17]]}}}